Pricing Strategy for Cell & Gene Therapies: Reimbursement Model Innovation
Description
Per-patient CGT costs $200K-$1M+. One-time vs. durable benefit pricing models unclear. Reimbursement denial risks. Strategic analysis of value-based pricing, risk-sharing, and patient access solutions for advanced therapies.
Table of Contents
75 Pages
- EXECUTIVE SUMMARY
- 1.1 CGT Market & Pricing Challenges
- 1.2 Reimbursement Landscape
- 2.0 VALUE-BASED PRICING FRAMEWORK
- 2.1 Willingness-to-Pay Analysis
- 2.2 Health Economics Studies
- 2.3 Payer Thresholds
- 3.0 RISK-SHARING AGREEMENTS
- 3.1 Outcomes-Based Contracts
- 3.2 Payment-for-Durability Models
- 3.3 Escrow Arrangements
- 4.0 GLOBAL PRICING STRATEGY
- 4.1 US Premium Positioning
- 4.2 International Pricing
- 4.3 Reference Pricing Impact
- 5.0 PATIENT ACCESS SOLUTIONS
- 5.1 Co-Pay Assistance
- 5.2 Access Programs
- 5.3 Equity Framework
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.



